Glenmark Pharmaceuticals Inc., USA has announced the launch of Vancomycin Hydrochloride for Injection USP in three dosage strengths: 750 mg/vial, 1.25 g/vial, and 1.5 g/vial in single-dose vials. The company confirmed that the product is bioequivalent and therapeutically equivalent to the reference listed drug from Mylan Laboratories Limited (NDA 209481).
According to IQVIA™ sales data for the 12-month period ending January 2025, the Vancomycin Hydrochloride for Injection USP market in these specific dosage forms achieved annual sales of approximately $39.3 million in the United States.
"We are excited to announce the launch of Vancomycin Hydrochloride for Injection USP, adding another quality product to our institutional portfolio," said Marc Kikuchi, President & Business Head, North America at Glenmark Pharmaceuticals.
Market Significance and Clinical Application
Vancomycin is a glycopeptide antibiotic widely used to treat serious infections caused by gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA). The drug remains a critical component in the antimicrobial arsenal for healthcare institutions, particularly for treating severe infections where other antibiotics may be ineffective due to resistance.
The introduction of Glenmark's generic version may help increase accessibility and potentially reduce costs for healthcare providers and patients requiring this important antibiotic therapy.
Company Profile and Global Presence
Glenmark Pharmaceuticals Ltd. is a research-led global pharmaceutical company with a diverse portfolio spanning branded, generic, and over-the-counter segments. The company focuses on therapeutic areas including cardio-metabolic, respiratory, dermatology, and oncology products.
With 11 manufacturing facilities across four continents and operations in more than 80 countries, Glenmark has established a significant global footprint. The company ranks among the Top 100 biopharmaceutical companies by pharmaceutical sales according to Scrip 100 (2023), and among the Top 50 generics and biosimilar companies by sales according to Generics Bulletin (2024).
Strategic Expansion in North America
This launch represents another step in Glenmark's strategy to strengthen its presence in the North American market, particularly in the institutional pharmaceutical segment. The company continues to leverage its research and manufacturing capabilities to bring equivalent generic alternatives to the market, potentially increasing competition and accessibility for important medications.
The addition of Vancomycin Hydrochloride for Injection to Glenmark's portfolio demonstrates the company's commitment to expanding its product offerings in the injectable antibiotics category, an essential component of hospital formularies and institutional care settings.
Environmental and Social Responsibility
Beyond its pharmaceutical operations, Glenmark has demonstrated commitment to environmental sustainability, with its Green House Gas emission reduction targets approved by the Science Based Target initiative in 2023—making it only the second pharmaceutical company in India to achieve this recognition. The company reports having impacted over 3.3 million lives through its corporate social responsibility interventions over the past decade.
